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Tristetraprolin Regulates Interleukin-6 Expression
Through p38 MAPK-Dependent Affinity Changes
with mRNA 3¢ Untranslated Region
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Tristetraprolin (TTP) is a well-characterized, zinc finger-containing, RNA-binding protein. TTP targets tumor
necrosis factor a for degradation via the 3¢ untranslated region (3¢UTR). Although AU-rich elements (AREs) in
the 3¢UTR of interleukin-6 (IL-6) mRNA dictate mRNA degradation, the role of TTP in the post-transcriptional
regulation of IL-6 gene expression is unclear. Here we used TTP-deficient mice to test the hypothesis that IL-6
expression is influenced by TTP. Genetic and siRNA-mediated knockdown of TTP resulted in increased IL-6
production and overexpression of TTP had the reverse effect. IL-6 and tumor necrosis factor a production were
elevated after injection of IL-1b in TTP-deficient mice. Further, embryonic fibroblasts from these mice (mouse
embryonic fibroblasts) exhibited greater IL-6 mRNA expression and longer half-life than wild-type mouse
embryonic fibroblasts. Overexpression of TTP reduced IL-6 3¢UTR luciferase reporter activity in an ARE-
dependent manner. Proximal and distal regions of the 3¢UTR acted synergistically to produce the full repression
of TTP. Mutation-based luciferase assays show that ARE2, ARE3, and ARE4 are required for TTP-mediated
repression. The constitutively activated p38-MK2 pathway abrogated TTP-mediated repression of IL-6 3¢UTR
reporter activity. RNA immunoprecipitation assay indicated that the deficiency of p38a resulted in the increased
affinity of TTP to IL-6 mRNA. Taken together, we propose that TTP downregulates IL-6 gene expression at the
post-transcriptional level by targeting ARE elements in the 3¢UTR region.
Introduction
Tristetraprolin (TTP), also known as ZFP36, TIS11,G0S24, and NUP475, is a member of a small family of
tandem CCCH zinc finger proteins. TTP has been shown to
bind to a variety of AU-rich sequences found in the 3¢ un-
translated region (3¢UTR) of transcripts, including sequences
from tumor necrosis factor a (TNFa), granulocyte macrophage-
colony stimulating factor (GM-CSF), and interleukin (IL)-2
(Patil and Kirkwood 2007; Khabar 2010). The TTP knockout
mouse exhibits a profound inflammatory syndrome with ero-
sive arthritis, autoimmunity, and myeloid hyperplasia, which
are reversed with administration of anti-TNFa antibody
(Varnum and others 1991; Taylor and others 1996). Over-
expression of TTP promoted the decay of reporter transcripts
that contained AU-rich sequences from TNFa (Lai and others
1999). In this context, TTP can be thought of as an anti-inflam-
matory protein. As a point of therapeutic potential, our lab
group has previously shown that TTP overexpressed in vivo at-
tenuated lipopolysaccaride-induced inflammation and bone de-
struction in a periodontal disease model (Patil and others 2008).
IL-6 is a multifunctional cytokine produced by a vast va-
riety of cell types, including lymphocytes, macrophages, fi-
broblasts, synovial cells, endothelial cells, glial cells, and
keratinocytes. IL-6 expression is induced by a variety of
stimuli, including IL-1, TNF, platelet-derived growth factor,
and lipopolysaccaride. There is significant evidence that IL-6
may play an important role in various diseases, including
inflammation and malignancies (Nishimoto 2010), including
evidence that IL-6 is constitutively overexpressed in synovial
tissues of rheumatoid patients (Hirano and others 2001). The
role of IL-6 in human malignancy is most clearly established
in multiple myeloma (Yoshio-Hoshino and others 2007;
Adachi and others 2008). Monoclonal antibodies enhance the
effectiveness of chemotherapy in this disease (Kastritis and
others 2009). There is also in vitro evidence that IL-6 can act
as an autocrine growth factor in a number of human epi-
thelial malignancies, including renal, lung, and prostate
cancer (Waldner and Neurath 2008; Kasuga and others 2001).
To clarify the mechanism involved in the abnormal expres-
sion of IL-6, it is important to investigate the mechanism of
IL-6 gene expression under physiological conditions.
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An adenine and uridine (AU)-rich element (ARE) in the
3¢UTR of cytokine transcripts is an important determinant of
post-transcriptional mRNA control. A hallmark of AREs is
the pentamer AUUUA that occurs either alone or clustered.
TNFa, GM-CSF, and IL-3 AREs are typical class II AREs with
a core AUUUA motif cluster (Khabar 2005, 2007, 2010). The
AREs of c-myc and c-fos are prototypes of class I, containing
1 to 3 scattered copies of the AUUUA motif, whereas another
group of cytokine transcripts including IL-2, IL-4, and IL-6
contain class I–like AREs. This fact is highlighted in the IL-6
transcripts that contain 5 AUUUA pentamers where none are
clustered together.
In recent years, significant information has accumulated
regarding the role of 3¢UTR of proinflammatory genes as
targets of mitogen-activated protein kinase (MAPK) p38
pathway, and many of the effects appear to be mediated by
its substrate, MAPK-activated protein kinase 2 (MK2)
(Kotlyarov and Gaestel 2002; Stoecklin and others 2004;
Sandler and Stoecklin 2008). It has been shown that p38
MAPK/MK2 cascade is involved in regulatingmRNA stability
via 3¢-UTRs of TNFa, IL-8, GM-CSF, COX-2, and VEGFmRNA
(Sandler and Stoecklin 2008). Inmacrophages the 3¢UTR of IL-6
is the downstream target of MK2, which is an essential com-
ponent of the mechanism that regulates mRNA stability. For
the IL-1b-induced IL-6 biosynthesis, the involvement of p38
in vivo at the post-transcriptional level has only recently been
explored (Patil and others 2004; Zhao and others 2008).
The mechanism by which TNFamRNA is targeted by TTP
has been intensely studied (Lai and others 1999; Rigby and
others 2005). However, the role of TTP in IL-6 regulation has
not been well studied since the TTP-null mouse does not ex-
hibit spontaneously elevated levels of IL-6. The role of TTP in
post-transcriptional regulation of IL-6 was the focus of the
present study. Our data support the idea that IL-6 mRNA is
highly expressed in IL-1b-stimulated, TTP-deficient mouse
embryonic fibroblasts (MEFs), and has a longer half-life than
wild-type MEFs through a mechanism that requires multiple
AREs within the 3¢UTR. This occurs in a p38-MK2-dependent
manner since an increased affinity of TTP to IL-6 mRNA is
observed in a p38a-null background. Taken together, we
propose that TTP downregulates IL-6 gene expression at the
post-transcriptional level by targeting the 3¢UTR.
Materials and Methods
Mice
TTP -/ - mice were generated as previously described
(Taylor and others 1996). Genotyping of offspring was per-
formed by polymerase chain reaction (PCR) analysis of tail
DNA using primers as described (Taylor and others 1996).
All mice were maintained in autoclaved microisolator cages
in a barrier facility. All animal care and experiments were in
accordance with the University of Michigan institutional
guidelines for animal use.
Cell culture
MEFs were derived from wild-type, p38a-/- , and TTP-/-
mice. The establishment of MEFs has been previously
described (Zhao and others 2008). Cells were grown in Dul-
becco’s minimal essential medium supplemented with 10%
fetal calf serum, 2mM glutamine, 100U of penicillin per mL,
and 100mg of streptomycin per mL, and incubated at 37C in
5% CO2. The MEFs were transfected using Lipofectamine Plus
Reagent (Invitrogen) according to the manufacturer’s protocol.
Cells were stimulated with IL-1b (1ng/mL) for the indicated
times.
Reagents
IL-6 enzyme-linked immunosorbent assay system and
recombinant mouse IL-1b were purchased from R&D Sys-
tems. The dual-Luciferase Reporter Assay System was pur-
chased from Promega. SB203580 and actinomycin D were
from Calbiochem and Invitrogen, respectively. Assays-on-
Demand Gene Expression Products (mIL-6 and mGAPDH)
and TaqMan Universal PCR Master Mix were from Applied
Biosystems.
Plasmids
pcDNA3-p38a, -p38AF, -MKK3E, and -MKK3E were gifts
from J. Han (Scripps Institute, La Jolla, CA). 3¢-UTR of mIL-6
was amplified by PCR using primers terminating in XbaI
recognition sequences. The establishment of full-length pGL3
IL-6 3¢UTR, truncations, and mutants has been described
previously (Zhao and others 2008).
Luciferase assay
Luciferase activity was determined using a luciferase as-
say system, following the manufacturer’s protocol (Promega
Corp.). Briefly, cell monolayers in 12-well plates were re-
moved by scraping into 200mL of reporter lysis buffer. Cells
were vortexed and cellular debris removed by centrifugation
(30 s at 12,000 · g). Luciferase activity was measured using
an LMax II 384 (Molecular Devices). A Renilla luciferase re-
porter vector (pEF-1 R-Luc) was included in every experi-
ment as a transfection efficiency control. Relative luciferase
activity was determined and normalized to Renilla luciferase
activity as previously described (Zhao and others 2008).
Real-time quantitative reverse
transcription-polymerase chain reaction
IL-6 mRNA expression was analyzed by reverse tran-
scription (RT)-PCR and Real-time PCR. First-strand cDNA
was synthesized from RNA (600 ng) using SuperScript III
Reverse Transcriptase (Invitrogen). First-strand cDNA was
used for PCR with specific oligonucleotide primers for mIL-6
(forward, 5¢ATGAAGTTCCTCTCTGCAAGAGACT3¢; re-
verse, 5¢CACTAGGTTTGCCGAGTAGATCTC3¢)and Real-
time PCR with primers designed by Applied Biosystems
(mIL-6, mm00446190; mGAPDH, mm99999915).
RNAi against mouse TTP in MEF cells
MEFs were transfected with 100 nM siRNA using Lipo-
fectamine 2000. After 24 h, cells were re-plated and trans-
fected again for another 24 h. Scrambled control siRNAs
were purchased from Ambion.
Immunoprecipitation of RNP complexes
and RT-PCR
Immunoprecipitation of endogenous RNA-protein com-
plexes was described previously. Cytoplasmic lysates, pre-
pared from wild-type and p38 -/ - MEFs, were incubated
(16 h, 4C) with 100 mL of a 50% (vol/vol) suspension of
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protein A-Sepharose beads precoated with 30ug each of
rabbit IgG1 or rabbit anti-TTP (Santa Cruz Biotechnology).
The beads were washed 5 times with cytoplasmic lysis buffer
(20mM Tris-Hcl [pH7.5], 100mM KCl, 5mM MgCl2, 0.3%
IGEPAL CA-630, and RNASEOUT [1,000U/mL]). RNA was
extracted using phenol and chloroform and precipitated in
ethanol. The RNA isolated from immunoprecipitaion (IP)
material was reverse transcribed using oligo(dT) primer.
Amplicon primers were used for murine IL-6 (accession no.
NM_031168.1; forward 5¢-atgaagttcctctctgcaagagact-3¢ and
reverse 5¢-cactaggtttgccgagtagatctc-3¢) and murine GAPDH
(accession no. NM_008084; forward 5¢-caccatggagaaggccg
ggg-3¢ and reverse 5¢-gacggacacattgggggtag-3¢). PCR prod-
ucts were run on a 1% agarose gel containing 0.5 mg/mL
ethidium bromide.
Results
TTP downregulates IL-1b-induced IL-6 production
To investigate the function of TTP in vivo, primary MEFs
were prepared from wild-type (TTP+/+ ) and TTP-/- em-
bryos, and stimulatedwith IL-1b for 24 h. IL-6 production from
culture supernatants was examined by enzyme-linked immu-
nosorbent assay (Fig. 1A). Remarkably, TTP-/- MEFs pro-
duced a 2-fold increase of IL-6 compared with wild-type
counterparts, in the presence or absence of IL-1b. To verify that
TTP downregulates IL-6 production, TTP was downregulated
by siRNA and overexpressed in MEF cells. Two different siR-
NAswere used to target TTP, thereby reducing TTP expression
to about 50% of its original level by RT-PCR (data not shown).
IL-6 production was decreased by overexpression of TTP (Fig.
1B), and increased by silencing TTP (Fig. 1C). These results
indicate that TTP inhibits IL-6 production.
TTP destabilizes endogenous IL-6 mRNA
The destabilizing effect of TTP on its target mRNA is as-
sociated with the direct binding of TTP via cis-elements at the
3¢UTR of the target mRNA. To investigate the mechanism by
which TTP regulates IL-6 production, the IL-6 mRNA level
was compared between wild-type and TTP -/ - MEFs. Total
mRNA of wild-type and TTP-/- MEFs were collected after
24 h of IL-1b treatment, and IL-6 mRNA levels were exam-
ined by real-time PCR. In TTP-/- MEFs, IL-6 mRNA was
upregulated compared with wild-type MEFs (Fig. 2A). To
examine the significance of the IL-6 3¢UTR, wild-type and
TTP -/ - MEFs were transiently transfected with control and
IL-6 3¢UTR reporter constructs (Fig. 2B). TTP -/ - MEFs
consistently had significantly higher (P < 0.05) luciferase ac-
tivity than wild-type cells. To determine whether TTP reg-
ulates IL-6 mRNA turnover, we investigated the half-life of
endogenous IL-6 mRNA from wild-type and TTP-/- MEFs
(Fig. 2C). After 24 h of IL-1b treatment, Actinomycin D was
added to MEFs and IL-6 mRNA level was measured by Real-
Time PCR at indicated time points. Figure 2C shows a rela-
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FIG. 1. TTP downregulates IL-6 production. (A)MEFs were cultured in the presence of IL-1b (1 ng/mL) for 24 h. The culture
supernatants were harvested, and IL-6 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). (B)
TTP +/+ and TTP -/ - MEFs were seeded into 12-well plates in duplicate and transfected with empty vector pcDNA3,
pcDNA3- TTP. After 24 h, the cells were left untreated or were stimulated with IL-1b (1 ng/mL) for 24 h. IL-6 from culture
supernatants was measured by ELISA. (C) TTP-/- MEFs were transfected twice during a period of 4 days with short
interfering RNAs (siRNAs) targeting TTP. Cells were treated with IL-1b (1 ng/mL) for 24 h post-transfection and IL-6
concentrations from supernatant were measured by ELISA. Data presented represent the average of duplicate experiments
repeated 3 times (n = 3; *P < 0.05). TTP, tristetraprolin; IL, interleukin; MEF, mouse embryonic fibroblast.
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tively longer half-life in TTP -/ - MEFs (t1/2 = 5.69 h) than in
wild-type cells (t1/2 = 2.55 h). Differences in mRNA half-life
reached significance at 3 h (P = 0.0347). These data indicate
that IL-6 mRNA was stabilized by TTP.
Activation of the p38-MAPK pathway abrogates
TTP-induced downregulation in IL-6 3¢UTR
luciferase activity
Activation of the p38-MAPK pathway has previously been
reported to inhibit TTP and thereby stabilizes ARE-mRNA
(Stoecklin and others 2004). Constitutive activation of p38 by
MKK3(E) induced a 2-fold increase of luciferase activity in
RAWmacrophages, whereas the dominant negativeMEKK(A)
showed no change (Fig. 3A). Overexpression of TTP reduced
the reporter-gene activity by 50% compared with the control
(pcDNA3). This reduction was abrogated by co-transfection
with constitutively active MEKK3(E) but not MEKK(A). These
results indicate that activation of the p38 MAPK pathway
blocks the TTP-mediated downregulation of IL-6 3¢UTR.
To further investigate the role of p38 in TTP regulation,
TTP +/ + and TTP -/ - MEFs were transiently transfected with
pGL3 promoter or pGL3-IL6-3¢-UTR luciferase reporter
genes, and Renilla luciferase (pEF-RLuc) vector as a control
for transfection efficiency. In wild-type cells expressing TTP,
the p38 inhibitor significantly decreased IL6 reporter activity,
whereas in TTP -/ - MEFs this effect of p38 was not observed
(Fig. 3B). These findings are consistent with a role for p38 in
TTP-mediated IL-6 3¢UTR luciferase activity. To investigate
whether p38 regulates TTP-mediated IL-6 mRNA stability,
TTP +/+ and TTP -/ - MEFs were stimulated by IL-1b for
24 h followed by incubation with Actinomycin D to arrest
ongoing mRNA transcription. The mRNA level of IL-6 was
measured by quantitative real-time PCR. Compared with
TTP -/- MEFs, TTP +/ + showed reduced stability of IL-6
mRNA, which was amplified in the presence of the p38 in-
hibitor (Fig. 3C). The half-life of TTP +/ + MEFs is 2.5 h,
TTP -/- MEFs is 5.8 h, TTP+/+ + SB is 1.4 h, and TTP -/ -
MEFs + SB is 3.6 h. There is a significant difference between
TTP +/+ and TTP -/- MEFs, and between TTP+/+ MEFs
and TTP +/+ MEFs + SB, but no significant difference be-
tween TTP KO and TTP KO+ SB. Together, these results
show that p38MAPK inhibits TTP-induced downregulation
of IL-6 mRNA.
The AU-rich 3¢UTR of IL-6 mRNA is a target of TTP
The 3¢UTR of IL-6 contains 5 AREs. Since AREs in the 3¢-
UTR of many cytokine mRNAs are responsible for both
FIG. 2. TTP destabilizes endogenous IL-6 mRNA. (A) TTP+/+ and TTP -/- MEFs were treated with IL-1b (1 ng/mL) for
24 h and mRNA was harvested. IL-6 mRNA expression was measured by quantitative real-time PCR and adjusted for
GAPDH. (B) TTP +/ + and TTP-/- MEFs were transiently transfected with pGL3promoter, pGL3-IL6-3¢-UTR. Renilla lucif-
erase (pEF-RLuc) vector was cotransfected as transfection efficiency control in all transient transfection experiments. Sig-
nificant differences in reporter expression between TTP +/+ and TTP-/- MEFs are indicated (*P< 0.05). The values represent
3 independent experiments, and each experiment was performed in duplicate. (C) TTP +/ + and TTP -/ - MEFs were stim-
ulated by IL-1b (1 ng/mL) for 24 h. Actinomycin D (10mg/mL) was added for indicated time points, and the mRNA level of
IL-6 was measured by quantitative real-time PCR. Data represent the average of 2 independent experiments (*P = 0.0347).
3¢UTR, 3¢ untranslated region; PCR, polymerase chain reaction.
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mRNA stability and translational control, we examined
whether TTP targets the 3¢-UTR of IL-6. The full-length
3¢UTR of IL-6 was inserted downstream of the luciferase
reporter-gene (Zhao and others 2008). Additionally, a series
of luciferase reporter gene constructs, containing the various
regions of IL-6 3¢UTR and the motifs mutated from AUUUA
to AGGGA, were generated (Zhao and others 2008).
pGL3-IL-6 3¢UTR and control plasmid were transiently
transfected into wild-type and TTP -/ - MEFs (Fig. 4A). Lu-
ciferase activity of the reporter gene with IL-6 3¢UTR was
increased more than 2-fold in TTP -/- MEFs compared with
wild-type MEFs. Overexpression of TTP in wild-type MEFs
resulted in a dramatic decrease (*90%) of luciferase ex-
pression of pGL3-IL-6 3¢UTR. The luciferase activity of both
pGL3-IL-6 3¢UTR(56–173) and pGL3-IL-6 3¢UTR (172–403)
was only reduced *50% of control, whereas the decreased
expression was abrogated in pGL3-IL-6 3¢UTR(1–70), which
includes none of the AREs. These findings suggested that
TTP represses IL-6 3¢UTR luciferase activity in an ARE-
dependent manner, and both proximal and distal regions are
required for the full reduction.
The full-length IL6 3¢UTR and all the mutants (Fig. 4A)
were co-transfected with TTP or pcDNA3 in RAW cells.
Overexpression of TTP reduced reporter activity of IL-6
3¢UTR to 50% of parental control vector, whereas this re-
duction is completely lost with M2, M3, and M4. TTP re-
duced 26% of reporter activity with M1, whereas 50% with
M5, similar to that observed with the wild-type IL6 3¢UTR.
These data strongly indicate that ARE5 is not required,
whereas ARE2, ARE3, and ARE4 are essential for targeting
TTP, and ARE1 is involved in this targeting.
p38a deficiency increased the affinity
of TTP to IL-6 3¢UTR
Finally, we were interested to determine whether p38a
signaling could regulate the ability of TTP to bind the IL-6
3¢UTR. An immunoprecipitation (IP) assay was carried out
under conditions that preserved endogenous RNP associa-
tions. Following RT-PCR analysis of the IP material em-
ploying IL-6 3¢UTR specific oligomers, an IL-6 product was
readily detected in the IP material obtained using an anti-
TTP antibody in p38a -/ - MEF cells stimulated by IL-1b,
whereas only residual amplification was observed in wild-
type MEF cells or serum control IP (Fig. 5). RT-PCR results
from total RNA showed that actually p38a -/ - MEF cells
FIG. 3. p38-MAPK pathway is involved in TTP effect on IL-6 3¢UTR. (A) Raw cells were transiently co-transfected with
pcDNA3, MKK3(E), MKK3(A), and/or TTP with pGL3-IL6-3¢-UTR. (B) TTP+/+ and TTP-/- MEFs were transiently
transfected with pGL3-IL6-3¢-UTR. Cells were stimulated by IL-1b (1 ng/mL) for 24 h with or without p38 inhibitor (SB). (C)
TTP +/+ and TTP-/- MEFs were stimulated by IL-1b (1 ng/mL) for 24 h with or without SB inhibitor. Actinomycin D (10mg/
mL) was added, and the mRNA level of IL-6 was measured by quantitative real-time PCR. Data represent the average of 3
independent experiments. *P = 0.014 at 2 h and P = 0.0229 at 3 h between TTP+/+ and TTP -/ - MEFs treated with SB
inhibitor.
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produced less IL-6 mRNA than that found in IL-1b stimu-
lated wild-type cells. These data strongly indicate that TTP
increases its ability to bind IL6 3¢UTR in p38a -/ - MEF cells.
Discussion
Cells of the immune system keep tight control over the
production of potentially harmful cytokines by repressing their
expression at the post-transcriptional level. TheARE, located in
the 3¢UTR of many cytokines (eg, GM-CSF, TNFa, IL-2, IL-3,
and IL-6) and other proinflammatory factors (eg, COX-2 and
MMP-13), plays a major role in post-transcriptional repression
(Bakheet and others 2003; Khabar and others 2005; Khabar
2010). AREs regulate mRNA stability via interactions with se-
quence-specific RNA-BPs, which influence 2 critical steps of
mRNA decay: deadenylation and/or the subsequent 3¢ to 5¢
exonuclease-mediated degradation. Despite the knowledge
that over 20 different proteins can bind to ARE segments, only
a subset of these RNA-BPs has been shown to influence the
stability or translational efficiency of their target mRNAs. TTP
and TTP-related proteins, BRF1 and BRF2, have a major reg-
ulatory role in controlling cytokine mRNAs (Stoecklin and
others 2002; Raineri and others 2004; Lykke-Andersen and
Wagner 2005). The present study expands this basic informa-
tion to show that TTP regulates IL-1b-induced IL-6 expression
through interactions with multiple IL-6 ARE elements in a p38
MAPK-dependent manner.
The function of TTP was elucidated through several
studies using TTP-deficient mice (Varnum and others 1991).
TTP -/- mice were shown to develop a generalized inflam-
matory condition, including an arthritic-like syndrome sec-
ondary to increased TNFa and GM-CSF levels (Taylor and
others 1996). In TTP -/ - mice, the increased cytokine pro-
duction was shown to be a result of increased mRNA sta-
bility (Carballo and others 1998, 2000). In this study, MEF
cells were established from TTP +/ + and TTP -/- mouse
embryos to examine the direct role of TTP in IL-6 regulation.
Consistent with previous observations, IL-6 expression is not
elevated in TTP -/ - MEFs until stimulated with IL-1b where
significantly more IL-6 production was observed versus
TTP +/+ MEFs. Similarly, data shown in this report indicate
that siRNA against TTP increased inducible IL-6 expression.
Recently, our research group has shown a similar effect with
regard to IL-6 expression in oral cancer cells where TTP is
FIG. 4. ARE of IL-6 mRNA is a target of TTP regulation. (A) Schematic of IL-6 3¢UTR truncation and site-directed mutant
reporter constructs (B) Wild-type MEFs were co-transfected with IL-6 3¢UTR luciferase reporters [full length (1–403), Non-
ARE (1–70), proximal ARE (56–173), and distal ARE (172–403)] along with pcDNA.TTP or pcDNA3 control vector for 48 h.
Firefly L-Luciferase values from cell extracts were measured and normalized to full-length reporter (1–403) cotransfected with
control vector. Results from 2 independent experiments, performed in duplicate, are presented. Significant differences be-
tween full-length reporter and deletion constructs are reported (*P < 0.05). (C) p38a +/ + MEFs were transiently co-transfected
with pcDNA.TTP or pcDNA3 along with pGL3promoter, pGL3-IL6 3¢UTR, or pGL3-IL-6 3¢UTR vectors containing the
indicated ARE mutants. Results represent 3 independent experiments measured in duplicate. Significant differences in
reporter expression between p are indicated (*P < 0.05). ARE, AU-rich element.
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silenced (Van Tubergen and others 2010). Nonpho-
sphorylated TTP usually binds to mRNAs to promote rapid
degradation. Overexpression studies have confirmed that
TTP as well as TTP family members, BRF1 and BRF2, induce
the degradation of mRNAs containing cytokine AREs ( Jiang
and others 2002; Stoecklin and others 2003; Sully and others
2004). Data from the present study is consistent with these
observations where TTP overexpression decreases IL-1b-
stimulated IL-6 expression. Consistent with TTP over-
expression data, we observed that IL-1b-induced IL-6 mRNA
was significantly more expressed in TTP-deficient cells with
an increased half-life of the IL-6 mRNA.
The p38 MAPK pathways have been shown in a variety
of systems to be an integral signaling component involved
with cytokine mRNA stability (Winzen and others 1999).
Previous data from our group have indicated that IL-6
regulation is highly dependent on p38 MAPK signaling in a
variety of cell types (Patil and others 2004, 2006; Rossa and
others 2006, 2008; Kirkwood and others 2007; Zhao and
others 2008). The clinical significance of this regulation was
also demonstrated through inhibition of inflammation and
bone loss using small molecule inhibitors against p38
MAPK (Kirkwood and others 2007) and more recently us-
ing siRNA strategies targeting the p38 downstream kinase,
MK2 (Li and others 2011). As part of these studies, we
demonstrated that activation of p38 MAPK via over-
expression of a constitutively active form of MAPK Kinase-
3 (MKK3E) was able to induce IL-6 ARE reporter activity
compared with the dominant negative form of MKK3
(MKK3A) but when TTP was co-expressed with MKK3A
then TTP was able to repress the inductive capacity of
MKK3E. Additionally, in TTP-deficient cells IL-6 ARE re-
porter activity was lost in the presence of a p38 MAPK
inhibitor, suggesting that TTP effects on IL-6 are highly
dependent upon the phosphorylation status of TTP. We
also demonstrated that the these effects were not limited
to the ARE reporter since IL-6 mRNA was not affected in
TTP-deficient cells treated with a p38 MAPK inhibitor
compared with wild-type cells. We conclude from these
studies that the TTP directs mRNA stability of IL-6 largely
in a p38 MAPK-dependent manner.
There are 5 AREs within the 3¢UTR of the IL-6 mRNA that
contribute toward the IL-6 mRNA stability. Previous data
from our group have defined several p38 MAPK-dependent
AREs within the 3¢UTR of the IL-6 mRNA (Zhao and others
2008). In these studies, multiple ARE elements were found to
be p38 dependent in reporter transactivation and mRNA
decay studies. The present study extends this information to
show that TTP can only reduce IL-6 ARE reporter activity
with the reporter constructs that contain ARE cis elements
within the reporter. Compared with vector control, TTP re-
duced ARE reporter activity in both proximal (IL-656–173) and
distal (IL-6172–403) reporters but not reporters that do not
contain an ARE (IL-61–70). Using site-directed mutagenesis,
AREs 1–5 have been independently eliminated of each of the
IL-6 ARE elements. Deletion or mutation of AUUUA motifs
could alter the components of mRNA-trans-factor complex
and affect the luciferase activity of reporter gene containing
the IL-6 3¢-UTR with mutated AUUUA motifs. Using this
approach, we identified ARE1, ARE2, and ARE5 as the cis-
elements regulated by p38a in IL-6–3¢-UTR (Zhao and others
2008). In those studies, mutation of ARE1 and ARE2 resulted
in the enhanced expression due to the deficiency of p38a
phosphorylation, whereas mutation of ARE5 decreased the
luciferase reporter expression in the presence of p38a, indi-
cating that p38a is required for the ARE1 and ARE2 to re-
press expression and for ARE5 to enhance expression. Data
from the present study indicate that ARE2, ARE3, and ARE4
are necessary for TTP to repress IL-6 3¢UTR expression. Thus,
although previous data suggest that ARE5 may be the most
important ARE target of IL-6 regulation in a p38 MAPK-
dependent manner, different ARE elements are required for
TTP-mediated decay of the IL-6 mRNA. However, we cannot
directly conclude this based upon the data presented here
and ongoing studies are being directed toward understand-
ing the molecular nature of ARE2, 3, and 4 and TTP inter-
action.
Molecular action of TTP involves phosphorylation and
cytoplasmic localization. TTP binds to AREs of cytokine
genes and targets them to the exosome for rapid degradation
(Lai and others 1999; Chen and others 2001). p38/MK2 sig-
naling is required for TTP phosphorylation (Carballo and
others 2001; Mahtani and others 2001; Zhu and others 2001),
which promotes nuclear export of TTP, an event that is
partially dependent upon binding to 14–3-3 proteins,
through phosphoserine residues ( Johnson and others 2002).
Additionally, 14–3-3 inhibits the activity of TTP by pre-
venting TTP association with stress granules where ARE-
mRNA decay occurs (Stoecklin and others 2004). Taken
together, these data support the importance of TTP cyto-
plasmic localization and highlight the complexity of cytokine
regulation and importance of spatially separate mRNA pools
within the cytoplasm. To help delineate the role of TTP to
interact with IL-6 3¢UTR within the cytoplasm, RNA im-
munoprecipitation experiments were conducted. Data from
these experiments suggest that in IL-1b-stimulated cells,
there is a higher affinity for TTP to interact with IL-6 mRNA
in the absence of p38 MAPK. Collectively, all of these data
indicate the IL-6 mRNA stability is regulated by TTP through
a change in affinity for the transcript that occurs in a p38
FIG. 5. p38a deficiency increased the affinity of TTP to IL-6
3¢UTR. p38 wild-type (WT) or p38a -/ - MEFs cells were ei-
ther unstimulated or stimulated with IL-1b for 4 h. Protein A
agarose beads coated with either anti-TTP or control normal
rabbit serum were immunoprecipitated with cell lysates
from indicated MEF cells with or without IL-1b stimulation.
RNA was extracted from IP products and reverse tran-
scription (RT)-PCR was performed to evaluate cDNA am-
plification of IL-6 or control GAPDH. Right panel RT-PCR
results are shown from preimmunopreciptated total RNA in
IL-1b-stimulated WT or p38a -/ - MEF cells. Representative
data from 2 independently performed experiments are pre-
sented. IP, immunoprecipitaion.
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MAPK-dependent manner and involves specific AREs
within the 3¢UTR of the IL-6 mRNA.
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